Prevalence of Past and Reactivated Viral Infections and Efficacy of Cyclosporine A as Monotherapy or in Combination in Patients with Psoriatic Arthritis—Synergy Study: A Longitudinal Observational Study

Table 3

Description of patients with acute viral seropositivity.

	Basal	Number of patients who developed a virus-correlated disease	Treatment of viral seropositivity	Systemic treatment of psoriatic arthritis during the study
HCV RNA (n = 17)	7 pos	0	No	5 CsA; 1 CsA + steroid + methotrexate; 1 CsA + biologic
HBsAg (n = 188)	6 pos	0	1 pt (lamivudine)	3 CsA; 2 CsA + MTX; 1 CsA + steroid + MTX
HSV-1 IgM (n = 115)	3 pos	0	No	1 CsA; 1 CsA + steroid; 1 CsA + steroid + MTX
HSV-2 IgM (n = 114)	3 pos	0	No	1 CsA; 1 CsA + steroid; 1 CsA + steroid + MTX
HHV-6 DNA (n = 12)	10 pos	0	No	7 CsA; 3 CsA + biologic
EBV IgM (n = 99)	1 pos	0	No	1 CsA + steroid + biologic
Parvovirus B59 IgM (n = 12)	1 pos	0	No	1 CsA

CsA: cyclosporine A; MTX: methotrexate.